title: Metformin induces a senescence-associated gene signature in breast cancer cells.
abstract: Diabetic patients taking metformin have lower incidence of breast cancer than those taking other anti-diabetic medications. Additionally, triple negative breast cancer (TNBC), a form of breast cancer disproportionately afflicting premenopausal African American women, shows atypical susceptibility to metformin's antiproliferative effect. The mechanisms involved in metformin's function in TNBC has not yet been fully elucidated. Therefore, we sought to identify pathways regulated by metformin in using the MDA-MB-468 TNBC cell model. Metformin dose-dependently caused apoptosis, decreased cell viability, and induced cell morphology/chromatin condensation consistent with the permanent proliferative arrest. Furthermore, gene expression arrays revealed that metformin caused expression of stress markers DDIT3, CYP1A1,and GDF-15 and a concomitant reduction in PTGS1 expression. Our findings show that metformin may affect the viability and proliferative capacity of TNBC by inducing an antiproliferative gene signature, and that metformin may be effective in the treatment/prevention of TNBC.
authors: Division of Basic Pharmaceutical Sciences, Xavier University of Louisiana, School of Pharmacy, 1 Drexel Drive, New Orleans, LA 70125, USA. cwilli35@xula.edu
authors: Christopher C
authors: CC
authors: Williams
authors: Brittany A
authors: BA
authors: Singleton
authors: Shawn D
authors: SD
authors: Llopis
authors: Elena V
authors: EV
authors: Skripnikova
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics*; D018929:Cell Culture Techniques; D016922:Cellular Senescence / Q000187:drug effects*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008687:Metformin / Q000494:pharmacology*
chemical_list: D008687:Metformin
references: Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61
references: 20947488
references: Oncotarget. 2012 Apr;3(4):395-8
references: 22565037
references: Cancer. 2012 Mar 1;118(5):1202-11
references: 21800293
references: J Pharmacol Exp Ther. 2002 Jun;301(3):1126-31
references: 12023546
references: Cancer Res. 2011 Jul 1;71(13):4366-72
references: 21540236
references: Cell Cycle. 2010 Nov 15;9(22):4461-8
references: 21088486
references: Cell Cycle. 2009 Jul 1;8(13):2031-40
references: 19440038
references: Cell Cycle. 2012 Jan 15;11(2):367-76
references: 22189713
references: J Biol Chem. 2007 Apr 6;282(14):10164-71
references: 17284450
references: Oncogene. 1999 Dec 20;18(55):7908-16
references: 10630643
references: Cell Cycle. 2010 Sep 15;9(18):3807-14
references: 20890129
references: Rev Endocr Metab Disord. 2007 Sep;8(3):185-98
references: 17464566
references: Mol Pharmacol. 2001 Apr;59(4):901-8
references: 11259636
references: Carcinogenesis. 2010 Apr;31(4):703-11
references: 20130018
references: Breast Cancer Res Treat. 2008 May;109(1):123-39
references: 17578664
references: Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
references: 19596646
references: Cancer Res. 2006 Nov 1;66(21):10269-73
references: 17062558
references: Cancer Prev Res (Phila). 2012 Mar;5(3):351-4
references: 22389436
references: Sci Rep. 2012;2:362
references: 22500211
references: JAMA. 2006 Jun 7;295(21):2492-502
references: 16757721
references: Cell Cycle. 2010 Mar 15;9(6):1057-64
references: 20305377
references: Environ Health Perspect. 1995 Nov;103 Suppl 8:275-81
references: 8741798
references: J Natl Cancer Inst. 2008 Apr 16;100(8):530-2
references: 18398091